Concepedia

Nathan O. Fuller

NO

Statistics

Publications

14

Citations

628

H-Index

13

Active since

2004

Affiliations

AstraZeneca (United States)(Current)

AstraZeneca (United Kingdom)

University of North Carolina at Chapel Hill

Pfizer (United States)

Nathan O. Fuller is an author at AstraZeneca (United States) specializing in medicinal chemistry, pharmacology, and drug discovery.

ORCID

Publications per year

2004–2020

14

Publications

14

Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6

William McCoull, Tony Cheung, Erica Anderson et al. · ACS Chemical Biology · 2018 · 139 citations · Full text

, , +14

Discovery of Pyrazolo[1,5-<i>a</i>]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors

William McCoull, Roman Abrams, Erica Anderson et al. · Journal of Medicinal Chemistry · 2017 · 78 citations · Full text

, , +17

Investigation of the Rh-Catalyzed Asymmetric Reductive Aldol Reaction. Expanded Scope Based on Reaction Analysis

Albert E. Russell, Nathan O. Fuller, Steven J. Taylor et al. · Organic Letters · 2004 · 63 citations

, , +14

Fragment-based Differential Targeting of PPI Stabilizer Interfaces

X. Guillory, M. Wolter, S. Leysen et al. · Journal of Medicinal Chemistry · 2020 · 50 citations · Full text

, , +17

CoREST Complex-Selective Histone Deacetylase Inhibitors Show Prosynaptic Effects and an Improved Safety Profile To Enable Treatment of Synaptopathies

Nathan O. Fuller, Antonella Pirone, Berkley A. Lynch et al. · ACS Chemical Neuroscience · 2018 · 49 citations

, , +17

1–5 of 14